Poseida Therapeutics (PSTX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Jan8

Roche Holding Acquires Shares in Poseida Therapeutics, Completes Merger

06:17

Dec9

Roche's Acquisition Offer for Poseida Therapeutics at $9.00 per Share with Potential Additional $4.00 Cash

22:09

Nov26

HC Wainwright & Co. Downgrades Poseida Therapeutics Rating to Neutral, Target Price Reduced to $9.00

14:34

Nov12

Poseida Therapeutics, Inc. discloses its focus on allogeneic cell therapy and gene drugs

02:17

Nov8

Poseida Therapeutics released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of 125.863M USD and EPS of -0.368

04:00

Poseida Therapeutics released FY2024 Q3 earnings on November 7 (EST), actual revenue 71.75M (forecast 16.25M), actual EPS 0.2082 (forecast -0.4175)

04:00

Schedules & Filings

Schedules

Filings

Nov7

Earning Release(EST)

FY2024 Q3 Earning Release (USD) Revenue 71.75 M, Net Income 20.24 M, EPS 0.2082

Aug5

Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 25.97 M, Net Income -31.37 M, EPS -0.3235

May14

Earning Release(EST)

FY2024 Q1 Earning Release (USD) Revenue 28.14 M, Net Income -24.27 M, EPS -0.2528

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change